Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Immunovant, Inc. Common Stock

IMVT

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Last trade $32.94
Day change -$0.34 (-1.02%)
Day range $32.47 – $33.88
Volume 371,065
Market cap $6.89B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.89B
Price / earnings
—
Price / book
10.48×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.46×

Profitability

Earnings per share
-$2.46
Return on assets
-66.88%
Return on equity
-77.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.31×
Quick ratio
7.31×
Cash ratio
6.94×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$395.01M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMVT, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$19.14M$17.69M$17.27M$15.44M$17.51M$26.02M$20.17M$19.78M
Research and development$85.01M$142.63M$142.29M$98.92M$114.25M$101.2M$93.65M$94.52M
Total operating expenses$104.16M$160.32M$159.55M$114.36M$131.76M$127.22M$113.83M$114.3M
Operating income-$104.16M-$160.32M-$159.55M-$114.36M-$131.76M-$127.22M-$113.83M-$114.3M
Interest expense$6.9M$7.1M$0$0$5.6M$6.34M$0$0
Income before taxes-$97.25M-$153.22M-$150.7M-$109.08M-$125.91M-$119.7M-$105.87M-$110.97M
Income taxes$0$0-$2.84M$1.55M$594K$913K$583K$152K
Net income-$97.25M-$153.22M-$147.86M-$110.64M-$126.5M-$120.61M-$106.45M-$111.12M
Net income attributable to common shareholders-$97.25M-$153.22M-$147.86M-$110.64M-$126.5M-$120.61M-$106.45M-$111.12M
EBITDA-$104.07M-$160.23M-$159.46M-$114.26M-$131.66M-$127.12M-$113.72M-$114.2M
Basic earnings per share-$0.47-$0.75-$0.73-$0.61-$0.73-$0.71-$0.64-$0.76
Diluted earnings per share-$0.47-$0.75-$0.73-$0.61-$0.73-$0.71-$0.64-$0.76

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?

Immunovant (IMVT) has gained 24.4% over the past four weeks and Wall Street analysts project a mean price target of $46.61, indicating a potential 30.5% upside from current levels of $35.71. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, though the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks Investment Research

Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know

Immunovant, Inc. (IMVT) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 1.1% over the past three months. The upgrade positions IMVT in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving earnings outlook.

GlobeNewswire Inc.

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026 on November 9, 2026, with a conference call hosted by majority stockholder Roivant Sciences. The company is a clinical-stage immunology firm developing anti-FcRn targeted therapies for autoimmune diseases, with ongoing clinical studies in Graves' disease, myasthenia gravis, and CIDP.

GlobeNewswire Inc.

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

GlobeNewswire Inc.

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.